The Week in Review: December 1 – December 8, 2017

Friday, December 8, 2017 News Recap: URGENT BC Patient and Caregiver Input Request: Vosevi. We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Personal Stories This week we have two great stories of triumphing over HepC: Aidain’s ‘I will never forget the day I found out I had hepatitis c’, and Patric...

Elevated Levels of HBV DNA and HBsAg May Increase Liver Cancer Risk

HealthDay News — Elevated levels of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) are associated with increased risks of liver cancer, according to a study published in the Journal of Gastroenterology and Hepatology. The researchers found that the risk of liver cancer was positively associated with increasing levels of HBV DNA and HBsAg in dose-response manners.The adjusted odds ratios [ORs] increased from 2.11 to 10.47  for those wi

Benitec and Biotron in the race for $3.5b Hepatitis B market

Chronic Hepatitis B, a currently incurable disease, is attracting growing attention among international biotechs. The World Health Organisation estimates 257 million people live with Hep B and up to 900,000 die each year from related diseases such as liver cancer and cirrhosis. In Australia, more than 232,000 people have chronic hepatitis B, according to lobby group Hepatitis Australia. “Deaths from primary liver cancer have been climbing faster tha

The Week in Review: September 29 – October 6, 2017

Friday, October 6, 2017 News Recap: Liver Cancer Two studies on liver cancer in the news last week highlighted the global prevalence and causes of this terrible disease.  The first showed a direct correlation between excess weight and cancer occurrence (including liver cancer) – Cancers linked to excess weight make up 40% of all US diagnoses, study finds, while the second focussed on the global incidence of primary liver cancer. Hepatitis B virus wa...

Reactivation Rate of Hepatitis B in Inflammatory Arthritis Tx With DMARDs

It's not only DAAs than can reactivate HBV. In patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs (DMARDs), rates of hepatitis B (HBV) reactivation differ between those whose disease is resolved and those with chronic HBV infection. Findings from the systematic review and meta-analysis were published in Arthritis Care & Research (Hoboken). Patients with chronic HBV generally have a 5-fold to 8-fold higher risk for HBV

The Week in Review: August 18 – August 25, 2017

Friday, August 25, 2017 News Recap: Public health issues Hep B risk warning: Tools used in procedures such as callus scraping and cutting toenails could become contaminated with the virus and remain contaminated because of the sterilization practices followed. Public health authorities in Owen Sound have identified a local foot care clinic as a potential source of hepatitis B and are warning patients – other than orthotics patients – to consult a doc...

Public health issues Hep B risk warning

Tools used in procedures such as callus scraping and cutting toenails could become contaminated with the virus and remain contaminated because of the sterilization practices followed. Public health authorities have identified a local foot care clinic as a potential source of hepatitis B and are warning patients – other than orthotics patients – to consult a doctor about getting tested for this disease. Grey Bruce Health Unit issued a public advisory Tu

Gilead Receives Approval in Canada for VEMLIDY™ (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

MISSISSAUGA, ON, June 19, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for VEMLIDY™ (tenofovir alafenamide, TAF) 25mg tablets, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. – VEMLIDY is a Once-Daily Treatment that Demonstrated Similar Efficacy with Improved Renal and Bone Laboratory Safety Parameters C

Couldn’t Attend World Hepatitis Summit? View All Presentations Here!

Message from Organizers of World Hepatitis Summit 2015 in Glasgow, Scotland Sept. 2-4, 2015: "On behalf of the World Hepatitis Summit partner organisations, we, the Summit Organising Committee, would like to thank you for your attendance and important role at the Summit. The Summit had over 600 delegates in attendance through the week representing over 90 countries – it truly was a global event. The feedback so far has been very positive and we reali

Sign TORONTO DECLARATION on VIRAL HEPATITIS!

The TORONTO DECLARATION: STRATEGIES TO CONTROL AND ELIMINATE VIRAL HEPATITIS GLOBALLY resulted from Toronto's Nov. 5-6, 2014 "First International Meeting on Hepatitis Cure & Eradication", hosted by Virology Education (http://www.virology-education.com). The FULL DECLARATION is printed BELOW (link: http://www.infectiousdiseasesonline.com/wp-content/uploads/2014/11/toronto_declaration_v1.0-final_logo.pdf). To ADD YOUR NAME to the Toronto Declaratio...